急性髓系白血病患者全基因组mRNA可变剪接临床意义评估
本研究在台湾大学医院新诊断的341例急性髓系白血病(AML)患者中探讨全基因组可变剪接(AS)模式的临床影响,并用癌症基因组图谱(TCGA)队列验证。AML细胞全基因组剪接模式与正常脐带血CD34+/CD38-细胞显著不同,TP53突变AML剪接异常程度尤其高。整体剪接模式异常是接受标准强化化疗AML患者总生存的独立不良预后因素,将其整合入2022欧洲白血病网(ELN)风险分层可在两个队列中将患者分为四个预后不同的组。
要点
- AML细胞全基因组剪接模式与正常脐带血CD34+/CD38-细胞显著不同
- TP53突变AML的全基因组剪接模式异常程度尤其高
- 整体剪接模式异常是强化化疗AML患者总生存的独立不良预后因素
核心结论
- 本研究证明AML患者差异全基因组剪接模式具有临床和生物学意义。
- 需要更大型前瞻性队列的进一步研究来确认这些发现。
研究设计与样本
- 在台湾大学医院新诊断的341例AML患者中探讨全基因组AS模式的临床影响,并用TCGA队列验证。
- 研究比较了正常脐带血CD34+/CD38-细胞与AML细胞的全基因组剪接模式。
主要发现
- AML细胞的全基因组剪接模式与正常脐带血CD34+/CD38-细胞显著不同。
- TP53突变AML的全基因组剪接模式异常程度尤其高。
- 整体剪接模式异常是接受标准强化化疗AML患者总生存的独立不良预后因素。
- 将整体剪接模式整合入2022 ELN风险分类,可在实验队列和TCGA队列中将AML患者分为四个预后不同的组。
- 鉴定出四个具有AS改变且在两个队列中均具有预后意义的基因。
关键数值与推荐
- 2022 ELN风险分类整合整体剪接模式后,在两个队列中均将AML患者分为四个预后不同的组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大型前瞻性队列的进一步研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aberrant alternative splicing (AS) is involved in leukemogenesis. This study explored the clinical impact of alterations in global AS patterns in 341 patients with acute myeloid leukemia (AML) newly diagnosed at the National Taiwan University Hospital and validated it using The Cancer Genome Atlas (TCGA) cohort. While studying normal cord blood CD34+ /CD38- cells, we found that AML cells exhibited significantly different global splicing patterns. AML with mutated TP53 had a particularly high degree of genome-wide aberrations in the splicing patterns. Aberrance in the global splicing pattern was an independent unfavorable prognostic factor affecting the overall survival of patients with AML receiving standard intensive chemotherapy. The integration of global splicing patterns into the 2022 European LeukemiaNet risk classification could stratify AML patients into four groups with distinct prognoses in both our experimental and TCGA cohorts. We further identified four genes with AS alterations that harbored prognostic significance in both of these cohorts. Moreover, these survival-associated AS events are involved in several important cellular processes that might be associated with poor response to intensive chemotherapy. In summary, our study demonstrated the clinical and biological implications of differential global splicing patterns in AML patients. Further studies with larger prospective cohorts are required to confirm these findings.
引用
- Yang YT, Yao CY, Chiu PJ, et al. Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia. Am J Hematol. 2023. PMID: 36855936. doi:10.1002/ajh.26893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。